Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by 2O2Ovisionon Mar 12, 2024 8:45pm
173 Views
Post# 35929571

Options at eoy 2023

Options at eoy 2023I can't remember who kept bringing up options vs blackout but the company finally posted the 20f on the American side and the usual table for options isn't clear to say the least. I had a very quick read in the car but now offline for a couple days so hopefully someone has the time to dig up the sec filing and copy and paste for everyone. About half way through the 100 pages. The funny thing is the options expiring in December are still listed as of Dec 31 and there are a couple notes about expiry extended when blackout is in effect. Anyway again supports a theory discussed by others. Then the fully vested totals a few pages down seems to include those options. I can't focus on this right now and could very well have glanced over too quickly but let's hope someone can dig though the details. Cheers
<< Previous
Bullboard Posts
Next >>